C0297002||Farnesylthiosalicylic acid
C1254351||lipid-polyethylene glycol-polymer hybrid nanoparticles
C0087111||treatment
C0017636||glioblastoma
C1254351||lipid-polyethylene glycol (PEG)-polymer hybrid nanoparticles
C0475358||tumour tissue
C1372955||active ingredient
C0003392||antineoplastic drug
C0297002||farnesylthiosalicylic acid
C0297002||farnesylthiosalicylic acid
C0087111||treatment
C0017636||glioblastoma
C0297002||Farnesylthiosalicylic acid
C1254351||poly(lactic-co-glycolic acid)-1,2 distearoyl-glycerol-3-phospho-ethanolamine-N [methoxy (PEG)-2000] ammonium salt
C1254351||PLGA-DSPE-PEG
C1254351||1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) hybrid nanoparticles
C4082130||prepared
C0220825||evaluated
C0596402||Cytotoxicity
C0297002||FTA-loaded nanoparticles
C0007634||rat glioma-2 (RG2) cells
C0220825||evaluated
C0007600||non-malignant cell line, L929
C0523160||Scanning electron microscopy studies
C1182795||smooth surface
C0332501||spherical in shape
C0297002||farnesylthiosalicylic acid
C0297002||FTA-loaded nanoparticles
C0596402||cytotoxic activity
C0007600||RG2 glioma cell lines
C1254351||1,2-dioleoyl-3-trimethylammonium-propane
C0024485||Magnetic resonance imaging
C0677043||histopathologic
C0220825||evaluation
C0431085||RG2 tumour cells
C0012644||rat glioma model
C0034716||Wistar rats
C1254351||drug
C0297002||FTA-loaded nanoparticles
C0475440||tumour size
C0297002||Farnesylthiosalicylic acid
C1254351||PLGA-DSPE-PEG-DOTAP hybrid nanoparticles
C0017636||glioblastoma